NCT02974803View on ClinicalTrials.gov

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 9, 2018

Primary Completion Date

July 29, 2020

Study Completion Date

July 29, 2020

Conditions
MelanomaBrain Metastases
Interventions
DRUG

Dabrafenib

Dabrafenib 150 mg twice a day until progression or unaccepted toxicity.

DRUG

Trametinib

Trametinib 2 mg once daily until progression or unaccepted toxicity.

Trial Locations (6)

B3H 1V7

QEII Health Sciences Centre, Halifax

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

M4N 3M5

Odette Cancer Centre, Toronto

M5G 2M9

University Health Network, Toronto

J1H 5N4

Centre hospitalier universitaire de Sherbrooke, Sherbrooke

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK